Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Retained Earnings (2020 - 2025)

Barinthus Biotherapeutics' Retained Earnings history spans 6 years, with the latest figure at -$304.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 27.95% year-over-year to -$304.1 million; the TTM value through Dec 2025 reached -$304.1 million, down 27.95%, while the annual FY2025 figure was -$304.1 million, 27.95% down from the prior year.
  • Retained Earnings reached -$304.1 million in Q4 2025 per BRNS's latest filing, down from -$293.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$73.0 million in Q1 2021 to a low of -$304.1 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$166.8 million, with a median of -$152.2 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: grew 12.22% in 2022, then crashed 94.14% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$108.6 million in 2021, then increased by 4.92% to -$103.2 million in 2022, then tumbled by 71.04% to -$176.6 million in 2023, then plummeted by 34.59% to -$237.7 million in 2024, then decreased by 27.95% to -$304.1 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Retained Earnings are -$304.1 million (Q4 2025), -$293.0 million (Q3 2025), and -$278.4 million (Q2 2025).